β-sitosterol, stigmasterol, quercetin, isorhamnetin, berberine, and anemoside B4 may be the material basis for BD treatment of UC, which exerts anti-inflammatory effects by regulating the expression of inflammatory factors and modulating the NF-κB signaling pathway. The gene discussed is NFKB1; the disease is Behcet disease.